Sign up to save your podcasts
Or
Share Ghassan Abou-Alfa, MD, MBA - The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ghassan Abou-Alfa, MD, MBA - The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond
Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies
View all episodes
By PVI, PeerView Institute for Medical Education
2.7
33 ratings
Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies
More shows like PeerView Gastroenterology CME/CNE/CPE Video Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
Gut Podcast
7 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
American Journal of Gastroenterology Author Podcasts
67 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
12 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
Huberman Lab
28,288 Listeners
Evidence-Based GI: An ACG Publication and Podcast
15 Listeners
Gastroenterology & Endoscopy
3 Listeners